|

Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

RECRUITINGN/ASponsored by Northwestern University
Actively Recruiting
PhaseN/A
SponsorNorthwestern University
Started2025-07-31
Est. completion2026-07-31
Eligibility
Age14 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT03932903

Summary

This is a small-scale micro-randomized clinical trial of a new mobile just-in-time adaptive intervention (JITAI) designed to promote oral chemotherapy adherence in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL). The goals of this study are to determine intervention feasibility and acceptability.

Eligibility

Age: 14 Years+Healthy volunteers accepted
AYA Inclusion Criteria:

* Ages 14-29
* Diagnosed with acute lymphoblastic leukemia (ALL) or lymphoma
* In the maintenance phase, completed at least one cycle and has at least one month of maintenance therapy remaining.
* Prescribed 6-mercaptopurine (6MP)
* English language proficiency
* For AYA \<18, must have informed consent from their caregiver.

AYA Exclusion Criteria:

* Cognitive impairments that would limit ability to complete measures, determined by the medical team
* Absence of inclusion criteria above.

Caregiver Inclusion Criteria:

* Nominated by the AYA as a primary caregiver involved in cancer care (can be a parent, relative, partner, friend)
* English language proficiency

Caregiver Exclusion Criteria:

\- Absence of inclusion criteria above.

Conditions3

Acute Lymphoblastic LeukemiaCancerLymphoblastic Lymphoma

Locations1 site

Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, 60611
Alexandra Psihogios, Ph.D.312-503-3577alex.psihogios@northwestern.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.